Abstract: The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.

Abstract: A display device includes a circuit substrate that is formed of a plurality of layers including a light control element; a counter substrate that faces a surface of the circuit substrate on which the light control element is disposed, with a gap therebetween; a seal that is disposed between the circuit substrate and the counter substrate to surround the light control element; and a filler with which a sealed space surrounded by at least the circuit substrate, the counter substrate, and a sealing surface of the seal is filled. The sealing surface includes internal angle corner surfaces formed by an inner surface of the seal, and a convex surface formed adjacent to the corner surfaces from at least one of the circuit substrate, the counter substrate, and the seal.

Abstract: Provided is a drug that allows highly-efficient skipping of exon. The present invention provides an antisense oligomer wherein two or more unit oligomers targeting sequences that are neither consecutive nor overlap with each other in the same exon are connected.

Abstract: The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.

Abstract: A method of manufacturing a display device, the display device including, a substrate, a circuit element layer including a semiconductor layer, an insulation layer and a conducting layer, a bump part including at least one layer selected from the semiconductor layer, the insulation layer and the conducting layer forming the circuit element, and a sealing film, the method is provided including forming the circuit element layer in a display region of a plurality of display panels on a first surface above the substrate, forming the bump part in a boundary region of the plurality of display panels, forming the sealing film on approximately the entire surface of the plurality of display panels, and dividing the display panels at the bump part by cutting the substrate.

Abstract: Provided is a drug that allows highly-efficient skipping of exon. The present invention provides an antisense oligomer wherein two or more unit oligomers targeting sequences that are neither consecutive nor overlap with each other in the same exon are connected.

Abstract: The present invention provides a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene.

Abstract: A display device includes a first substrate, a light emitting element located on the first substrate and including a pair of electrodes and one organic layer or a plurality of organic layers located between the pair of electrodes, a second substrate located to face the first substrate, a third substrate located on a surface of the second substrate opposite to a surface thereof facing the light emitting element, and a tacky layer located between the second substrate and the third substrate, a tack strength between the tacky layer and the second substrate or the third substrate being weaker than an adhesive strength between one of the pair of electrodes and the one organic layer or an adhesive strength between the plurality of organic layers.

Abstract: A display device is disclosed including an array substrate including a plurality of pixels arranged in a display region, the display region including a planar region and a curved region, and a sealing layer covering the plurality of pixels and arranged across the display region, wherein the sealing layer includes a first organic insulation layer and a second organic insulation layer, a film thickness of the first organic insulation layer is more than a film thickness of the second organic insulation layer in the planar region, a film thickness of the second organic insulation layer is more than a film thickness of the first organic insulation layer in the curved region, and a hardness of the second organic insulation layer is lower than a hardness of the first organic insulation layer.

Abstract: A display device includes a first substrate having a first step part formed in a frame area on a periphery of a display area, a second substrate arranged facing the first substrate, and a filler material filled between the first substrate in one part of the display area and the frame area, and the second substrate, a periphery edge part being located in a range from the first step part to an end part of the first substrate and the second substrate.

Abstract: A display device includes a first substrate, a light emitting element located on the first substrate and including a pair of electrodes and one organic layer or a plurality of organic layers located between the pair of electrodes, a second substrate located to face the first substrate, a third substrate located on a surface of the second substrate opposite to a surface thereof facing the light emitting element, and a tacky layer located between the second substrate and the third substrate, a tack strength between the tacky layer and the second substrate or the third substrate being weaker than an adhesive strength between one of the pair of electrodes and the one organic layer or an adhesive strength between the plurality of organic layers.

Abstract: Provided is a drug that allows highly-efficient skipping of exon. The present invention provides an antisense oligomer wherein two or more unit oligomers targeting sequences that are neither consecutive nor overlap with each other in the same exon are connected.

Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.

Abstract: A display device includes a first substrate provided with at least one color filter layer that transmits light of a certain wavelength, a second substrate that is disposed opposed to the first substrate; and a fill layer disposed between the first substrate and the second substrate. The first substrate is provided with a display region in which the at least one color filter layer is disposed and which displays an image and a peripheral region that is positioned out of the display region. Wettability of a surface of the at least one color filter layer of the peripheral region is equal to or less than wettability of a surface of the at least one color filter layer of the display region.

Abstract: Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.

Abstract: The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.

Abstract: A method includes: forming, in a first substrate, a display area in which a plurality of pixels including an organic EL light-emitting layer are arrayed; forming, in a second substrate, a plurality of opening areas respectively located in correspondence with the plurality of pixels and a light-blocking area that demarcates the plurality of opening areas; providing a dam material such that the dam material encloses the display area; dripping a filler material to an area enclosed by the dam material; and attaching the first substrate and the second substrate to each other, and fusing together dripped portions of the filler material, thereby bonding the both substrates to each other. The both substrates are attached to each other while being positionally aligned such that borders between the dripped portions of the filler material that is generated by the fusion are located in an area corresponding to the light-blocking area.

Abstract: The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.

Abstract: A method includes: forming, in a first substrate, a display area in which a plurality of pixels including an organic EL light-emitting layer are arrayed; forming, in a second substrate, a plurality of opening areas respectively located in correspondence with the plurality of pixels and a light-blocking area that demarcates the plurality of opening areas; providing a dam material such that the dam material encloses the display area; dripping a filler material to an area enclosed by the dam material; and attaching the first substrate and the second substrate to each other, and fusing together dripped portions of the filler material, thereby bonding the both substrates to each other. The both substrates are attached to each other while being positionally aligned such that borders between the dripped portions of the filler material that is generated by the fusion are located in an area corresponding to the light-blocking area.